Organogenesis Holdings Inc. Share Price & Technical Analysis

ORGO · $2.66 (0.00%)

Healthcare / Drug Manufacturers - Specialty & Generic

AI Score 47 · Weak

$2.66

0.00%

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extra

Price chart

Seasonality

May has 3 positive and 2 negative years (last 5 years shown)

17% return in May, 17% avg return in past 3 year May month.

-52% return in 2026, 68% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
26-23%-20%-23%-4%17%-52%
2516%72%-28%14%-45%32%28%13%-16%0%21%0%106%
24-17%9%-10%-21%17%0%3%-3%4%-3%39%-18%-1%
23-4%0%-16%-5%80%-8%30%-35%14%-29%14%58%99%
22-17%-4%0%-16%-12%-16%16%-37%-11%0%-18%0%-115%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 47/100

Weak · Downtrend · Uptrend

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$309.46M

P/E ratio

52W high

$7.08

52W low

$2.04

Volume

4,87,998

Beta

1.31

Related stocks in Healthcare

Frequently asked questions

What is Organogenesis Holdings Inc. share price today?
Organogenesis Holdings Inc. (ORGO) last traded around $2.66 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does ORGO have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ORGO. Download the app for real-time alerts.
How can I analyze Organogenesis Holdings Inc. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro